Sangamo Therapeutics Inc (NASDAQ:SGMO)’s share price rose 6.6% on Tuesday . The stock traded as high as $14.86 and last traded at $14.79. Approximately 1,467,241 shares traded hands during trading, a decline of 35% from the average daily volume of 2,273,491 shares. The stock had previously closed at $13.88.

SGMO has been the subject of several research reports. BidaskClub raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 20th. Bank of America began coverage on Sangamo Therapeutics in a research report on Wednesday, June 20th. They set a “buy” rating and a $24.00 target price on the stock. Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 17th. Cowen restated a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. Finally, Wedbush restated a “hold” rating and set a $9.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, July 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.00.

The stock has a market capitalization of $1.72 billion, a PE ratio of -21.00 and a beta of 2.97. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $21.42 million for the quarter, compared to analysts’ expectations of $21.43 million. Sangamo Therapeutics had a negative return on equity of 26.36% and a negative net margin of 105.65%. The company’s revenue was up 159.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. As a group, analysts forecast that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current fiscal year.

In other Sangamo Therapeutics news, Director H Stewart Parker acquired 2,000 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average price of $13.52 per share, for a total transaction of $27,040.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kathy Yi sold 5,000 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $13.97, for a total value of $69,850.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares in the company, valued at approximately $171,132.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,000 shares of company stock worth $430,950. Company insiders own 1.20% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Riverhead Capital Management LLC raised its position in shares of Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,667 shares in the last quarter. Mount Yale Investment Advisors LLC raised its position in shares of Sangamo Therapeutics by 2,202.8% in the second quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,996 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Sangamo Therapeutics in the second quarter worth $125,000. Tyers Asset Management LLC raised its position in shares of Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 7,232 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Sangamo Therapeutics in the second quarter worth $155,000. Institutional investors own 63.84% of the company’s stock.

Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: What are the benefits of buying treasury bonds?

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.